StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.

All GlobeNewswire news

DALLAS, Nov. 18, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Arena Pharmaceuticals Inc. (Nasdaq:ARNA). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Arena Pharmaceuticals Inc. (Nasdaq:ARNA) should be of particular interest to comparable companies: Johnson & Johnson DC (NYSE:JNJ), Watson Pharmaceuticals Inc. (NYSE:WPI) and King Pharmaceuticals (NYSE:KG).

The full report is available at: http://www.stockpreacher.com/n/ARNA

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Arena Pharmaceuticals Inc. (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a phase III clinical trial program for the treatment of obesity.

Message Board Search for ARNA: http://www.boardcentral.com/boards/ARNA

In the report, the analyst notes:

"Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share.

"In late October, ARNA reported data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) phase III trial that demonstrated improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings added to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients. The late-breaking data were presented by Lee Kaplan, M.D., Ph.D., associate professor of Medicine at Harvard Medical School and director of the Massachusetts General Hospital Weight Center, at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society."

To read the entire report visit: http://www.stockpreacher.com/n/ARNA

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT:  StockPreacher.com
          Jeff Bishop
          (469)-252-3505
          press@beaconequity.com

GlobeNewswire, Inc.2009

Back to News Home

MSN Money

Search MSN Money

Message Boards

Site Status